SINOVAC Named BogotáBio Exclusive Partner, Fueling New Vaccine Advances in Colombia

Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced it has been named the exclusive strategic partner of BogotáBio, which will break ground as the first local human vaccine production facility to be established in Colombia’s capital city of Bogota.

BogotáBio, implementing an innovative collaboration model between the public and private sectors in the pharmaceutical sector in Bogota, aims to develop a range of vaccines that effectively address Colombia’s pressing need for immunization against various infectious diseases.

 

SINOVAC was selected by Bogota government as the winner among 15 biopharmaceutical companies invited globally through a tender process. The Company's extensive expertise and experience in vaccine R&D and production, and successful track record establishing vaccine manufacturing facilities will play a pivotal role in the new venture.

 

"BogotáBio will be one of the greatest innovations that we leave for Bogota in terms of research, development, and healthcare,” said Claudia López, mayor of Bogota, as she described the new facility’s impact during the 2023 Smart City Expo Bogotá.